Tscan therapeutics reports second quarter 2024 financial results and provides corporate update

Fda grants rmat designation to tsc-100 and tsc-101 for the treatment of patients with aml, all, and mds undergoing allogeneic hct with reduced intensity conditioning
TCRX Ratings Summary
TCRX Quant Ranking